(R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine | 149549-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine
• 英文别名: N-(1-cyclohexylethyl)-4-phenylphthalazin-1-amine
• CAS: 149549-14-4
• 化学式: C₂₂H₂₅N₃
• 分子量: 331.5
• InChiKey: OJBBUQUNTTVULM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
  申请人：Mitsubishi Chemical Corporation

  公开号：EP0682947A1

  公开（公告）日：1995-11-22

  A medicament for the therapeutic and prophylactic treatment of a disease caused by smooth muscle cell hyperplasia which comprises as an active ingredient an aminopyridazine derivative or a salt thereof represented by the following Formula (I), e.g. (R) - 1 - (cyclohexylethylamino) - 4 - phenylphthalazine.

  一种用于治疗和预防由平滑肌细胞增生引起的疾病的药物，其活性成分包括胺哒嗪衍生物或由下式(I)代表的盐，例如(R)-1-(环己基乙氨基)-4-苯基酞嗪。
• Obesity small molecules
  申请人：Akron Molecules GmbH

  公开号：EP2633884A1

  公开（公告）日：2013-09-04

  The present invention relates to new therapies to treat obesity and related diseases, as well as for reducing triglyceride levels and body weight.

  本发明涉及治疗肥胖症和相关疾病以及降低甘油三酯水平和体重的新疗法。
• FMO3 inhibitors for treating pain
  申请人：Akron Molecules GmbH

  公开号：EP2674161A1

  公开（公告）日：2013-12-18

  The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

  本发明涉及治疗疼痛和相关疾病的新疗法，以及用于上述疗法的药物化合物。
• 3,6-Disubstituted pyridazine derivatives
  申请人：Mitsubishi Chemical Corporation

  公开号：EP0534443B1

  公开（公告）日：1998-12-30
• OBESITY SMALL MOLECULES
  申请人：Akron Molecules GmbH

  公开号：EP2521594A2

  公开（公告）日：2012-11-14